Beobachten
- Pressemitteilung BoxID 512361
Lophius Biosciences Completes Necessary Regulatory Milestones with EN ISO 13485 Certification and CE Marking for Both In Vitro Diagnostic T-Track® CMV/EBV Test Systems
(PresseBox) (Regensburg, )
Lophius Biosciences, a leader in the field of novel T-cell based diagnostic test systems, today announced the successful realization of two important regulatory milestones. With the successful completion of the EN ISO 13485 certification, the company established all prerequisites for a quality management system to meet customer and regulatory requirements applicable to medical devices according to the European IVD guidelines.
In addition, the company announced that it has received CE-marking for its T-Track® CMV and T-Track® EBV tests following successful clinical validation of both products by measuring functional effector cells of the cell-mediated immune system (CMI) in a cohort of > 120 hemodialysis patients. Observed clinical sensitivities in this patient cohort were 88-100% for T-Track® CMV and 86-97% for T-Track® EBV respectively, depending on the biostatistical method applied.
"We are very pleased with the successful completion of these important regulatory milestones which round up our development programs for both tests T-Track® CMV and T-Track® EBV. We now have the tools in place to establish full clinical benefits of these novel T-cell based diagnostics in the field of transplantation and other indications with high medical need" said Dr. Michael Lutz, CEO of Lophius Biosciences.
In addition, the company announced that it has received CE-marking for its T-Track® CMV and T-Track® EBV tests following successful clinical validation of both products by measuring functional effector cells of the cell-mediated immune system (CMI) in a cohort of > 120 hemodialysis patients. Observed clinical sensitivities in this patient cohort were 88-100% for T-Track® CMV and 86-97% for T-Track® EBV respectively, depending on the biostatistical method applied.
"We are very pleased with the successful completion of these important regulatory milestones which round up our development programs for both tests T-Track® CMV and T-Track® EBV. We now have the tools in place to establish full clinical benefits of these novel T-cell based diagnostics in the field of transplantation and other indications with high medical need" said Dr. Michael Lutz, CEO of Lophius Biosciences.
Über Lophius Biosciences GmbH
Lophius Biosciences GmbH develops and markets innovative T-cell based testing systems for diagnostics and possible therapy control in the fields of transplantation, infection and autoimmune diseases.
Diese Pressemitteilungen könnten Sie auch interessieren
|
Auf einen Klick die Nase vorn
, Medizintechnik, Heraeus Kulzer GmbH
Heraeus Kulzer macht es Zahntechnikern noch einfacher, sich fachlich auf dem neusten Stand zu halten. Die neue Kurs-Website unter www.heraeus-kulzer.com/kursprogramm...
|
Werkzeug- und Formenbauer beschäftigen sich mit Medizintechnik
, Medizintechnik, IPH - Institut für Integrierte Produktion Hannover gemeinnützige GmbH
"Werkzeugtechnologien für die Medizintechnik" sind das Schwerpunktthema des nächsten Treffens des Arbeitskreis Werkzeug- und Formenbau. Am 13. Juni 2013 tagt das...
|
Attraktive und günstige Cloud-Abrechnungslösung für Heilmittelleistungen
, Medizintechnik, Deutsches Medizinrechenzentrum GmbH
Heilmittel einfach über das Internet abrechnen. Für alle Leistungserbringer im Bereich Heilmittel stellt das Deutsche Medizinrechenzentrum (DMRZ) im Mai auf gleich...
